Event Calendar

Keiretsu Forum Southern California

Thursday, Mar 12 / 2026
Virtual Meeting
Download for Outlook/Apple Calendar Add to Google Calendar

March 2026 Virtual Investor Forum

Exceptional Companies. Real Dialogue. Strategic Capital.

Our next Keiretsu Forum SoCal Investor Forum is set to deliver another high-impact lineup of companies pushing the edge of innovation.

We review significant deal flow — and only a select few make it to Forum presentation.

Expect:
• Focused 5-minute investor-ready presentations
• Candid Q&A and peer dialogue
• Syndication potential across our global network
• Direct access to founders building what’s next

This is where alignment happens before capital moves.

Join us.

Presenting companies:

Sinaptica
Sinaptica

Sinaptica is advancing an Alzheimer's breakthrough with two completely successful randomized sham-controlled Phase 2 trials that met every FDA endpoint, significantly slowing disease progression with zero SAEs. Results published, presented, peer-reviewed, endorsed by top KOLs, and better than any drug. Originating from Harvard, our patented 20min weekly therapy has blockbuster sales potential, given high-margin recurring revenue from newly granted Medicare CPT reimbursement codes est. to pay $20k+ per year. We're Pivotal-ready and on an accelerated FDA path to disrupt one of the largest blue ocean markets in medicine as soon as 2029.

Cycling Designs
Cycling Designs

Cycling Designs’ product, Cyclesight, provides a real-time view of rear-approaching vehicles, allowing cyclists to react and avoid danger. spend considerable money on safety but there are still too many accidents and deaths. Cyclists can’t avoid what they can’t see. Cycling Desings sold 50 beta units to provide proof of concept and are now going to market with a phone app to provide the increased functionality that cyclists prefer and gives them a significant competitive advantage.

Nápreva
Nápreva

Nápreva manufactures the first non-addictive, pharmaceutical-quality terpene products for chronic pain relief. Sold as dietary supplements but produced to pharmaceutical manufacturing standards, Nápreva delivers consistent dosing, dependable quality, safety, and reliable results. With more than 800 customers, increasing daily, nearly 12% become repeat customers without incentives or price concessions. This offers significant validation of product benefits, but demonstrates potential for high-margin, high LTV customers.

Pharma in silica
Pharma in silica

Pharma in silica’s precision chemotherapy attacks solid tumors while sparing patients painful, maiming and costly adverse effects imposed by current chemo. OpPacli™ is fifteen months to FDA Phase Ib/IIa 515(b)(2) clinical trial against NSCLC. In 2028, the nanocarrier platform will enable pharmas to capture the chemo drugs US$ 25B market.